MXPA00012703A - Oligonucleotidos antisensibles para tratar o prevenir enfermedades atopicas y proliferacion celular neoplastica. - Google Patents

Oligonucleotidos antisensibles para tratar o prevenir enfermedades atopicas y proliferacion celular neoplastica.

Info

Publication number
MXPA00012703A
MXPA00012703A MXPA00012703A MXPA00012703A MXPA00012703A MX PA00012703 A MXPA00012703 A MX PA00012703A MX PA00012703 A MXPA00012703 A MX PA00012703A MX PA00012703 A MXPA00012703 A MX PA00012703A MX PA00012703 A MXPA00012703 A MX PA00012703A
Authority
MX
Mexico
Prior art keywords
antisense oligonucleotides
treating
present
cell proliferation
neoplastic cell
Prior art date
Application number
MXPA00012703A
Other languages
English (en)
Inventor
Paolo Renzi
Original Assignee
Rech S Expertises Et Dev Medic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rech S Expertises Et Dev Medic filed Critical Rech S Expertises Et Dev Medic
Publication of MXPA00012703A publication Critical patent/MXPA00012703A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
MXPA00012703A 1998-06-17 1999-06-17 Oligonucleotidos antisensibles para tratar o prevenir enfermedades atopicas y proliferacion celular neoplastica. MXPA00012703A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002235420A CA2235420A1 (en) 1998-06-17 1998-06-17 Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
PCT/CA1999/000572 WO1999066037A2 (en) 1998-06-17 1999-06-17 Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation

Publications (1)

Publication Number Publication Date
MXPA00012703A true MXPA00012703A (es) 2003-07-14

Family

ID=4162352

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA00012703A MXPA00012703A (es) 1998-06-17 1999-06-17 Oligonucleotidos antisensibles para tratar o prevenir enfermedades atopicas y proliferacion celular neoplastica.

Country Status (10)

Country Link
US (3) US6822087B1 (es)
EP (1) EP1088065B1 (es)
JP (1) JP4612188B2 (es)
AT (1) ATE312911T1 (es)
AU (1) AU758447B2 (es)
CA (1) CA2235420A1 (es)
DE (1) DE69928932T2 (es)
MX (1) MXPA00012703A (es)
NZ (1) NZ509308A (es)
WO (1) WO1999066037A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2235420A1 (en) * 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
US6566132B1 (en) * 2001-04-26 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Interferon gamma receptor 1 expression
DK1406667T3 (da) * 2001-07-06 2008-06-16 Topigen Pharmaceuticals Inc Fremgangsmåder til at öge oligonukleotiders in vivo-effektivitet og hæmme inflammation hos pattedyr
AU2003268032A1 (en) * 2002-07-29 2004-02-16 Epigenesis Pharmaceuticals, Inc. Composition and methods for treatment and screening
BRPI0414886A (pt) 2003-09-29 2006-12-12 Topigen Pharma Inc composições de oligonucleotìdeo e métodos para o tratamento de doença incluindo condições inflamatórias
TW200526777A (en) * 2003-11-12 2005-08-16 Combinatorx Inc Combinations for the treatment of proliferative diseases
AU2005330566B2 (en) * 2004-04-29 2008-09-18 Yale University Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases
ES2450929T3 (es) * 2004-10-29 2014-03-25 Topigen Pharmaceuticals Inc. Oligonucleótidos antisentido para tratar la alergia y la proliferación de las células neoplásicas
EP2316941A3 (en) * 2005-02-25 2012-03-14 Isis Pharmaceuticals, Inc. Compositions and their uses directed to IL-4R alpha
WO2007041719A2 (en) * 2005-10-03 2007-04-12 Isis Pharmaceuticals, Inc. Combination therapy using budesonide and antisense oligonucleotide targeted to il4-receptor alpha
US20070270366A1 (en) * 2005-12-20 2007-11-22 Karras James G Double stranded nucleic acid molecules targeted to il-4 receptor alpha
CA2652539A1 (en) 2006-05-19 2007-11-29 Topigen Pharmaceuticals Inc. Oligonucleotides affecting expression of phosphodiesterases
AU2009246000B2 (en) 2008-05-15 2014-09-04 Topigen Pharmaceuticals Inc. Oligonucleotides for treating inflammation and neoplastic cell proliferation
US8341614B2 (en) * 2008-06-06 2012-12-25 Apple Inc. Memory management for closures
JP2014502953A (ja) 2010-08-16 2014-02-06 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 細胞透過性治療薬の鼻腔内送達
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6806061B1 (en) * 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor
US5874211A (en) 1995-04-13 1999-02-23 Incyte Pharmaceuticals, Inc. Chemokine expressed in eosinophils
FR2734147B1 (fr) 1995-05-19 1997-10-10 Klein Jean Michel Dispositif d'osteosynthese implantable
FR2735984B1 (fr) 1995-06-30 1997-09-19 Inst Nat Sante Rech Med Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
WO1997023244A1 (en) 1995-12-22 1997-07-03 Smithkline Beecham Corporation Use of antisene oligodeoxynucleotides to produce truncated proteins
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
EP1012190A4 (en) 1996-04-26 2004-04-28 Merck & Co Inc EOSINOPHILIC EOTAXIN RECEPTOR
JP2000510690A (ja) 1996-04-26 2000-08-22 インサイト・ファーマスーティカルズ・インコーポレイテッド 哺乳類混合リンパ球受容体、ケモカイン受容体（ｍｍｌｒ―ｃｃｒ）
EP1019065A4 (en) * 1997-09-17 2002-02-20 Univ East Carolina VARIETY OF TARGETED, HYBRIDIZING NUCLEIC ACIDS, THEIR SYNTHESIS, COMPOSITION, FORMULATION, KITS AND APPLICATION
CA2235420A1 (en) * 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation

Also Published As

Publication number Publication date
JP2002518007A (ja) 2002-06-25
AU758447B2 (en) 2003-03-20
WO1999066037A3 (en) 2000-04-20
DE69928932D1 (de) 2006-01-19
JP4612188B2 (ja) 2011-01-12
EP1088065A2 (en) 2001-04-04
NZ509308A (en) 2003-05-30
US6822087B1 (en) 2004-11-23
CA2235420A1 (en) 1999-12-17
ATE312911T1 (de) 2005-12-15
US20050282762A1 (en) 2005-12-22
WO1999066037A2 (en) 1999-12-23
US7629324B2 (en) 2009-12-08
AU4493299A (en) 2000-01-05
US20100286239A1 (en) 2010-11-11
DE69928932T2 (de) 2006-09-07
EP1088065B1 (en) 2005-12-14

Similar Documents

Publication Publication Date Title
MXPA00012703A (es) Oligonucleotidos antisensibles para tratar o prevenir enfermedades atopicas y proliferacion celular neoplastica.
Chaouchi et al. Characterization of transforming growth factor-beta 1 induced apoptosis in normal human B cells and lymphoma B cell lines.
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
WO2000071703A3 (en) Inhibition of histone deacetylase
PL326082A1 (en) Seeds dropping
UA49006C2 (uk) Похідні 6-фенілпіридил-2-аміну, фармацевтична композиція, спосіб інгібування синтази оксиду нітрогену у ссавців та спосіб лікування
DE60103052D1 (de) Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
NZ329202A (en) Treatments for ameliorating the effects of psoriasis using compounds that inhibit cell proliferative and/or inflammation
IL134042A0 (en) Modified dorsal tissue affecting factor and compositions
WO1996011266A3 (en) Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein
ZA993777B (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases.
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
JP2002518007A5 (es)
WO1999027098A3 (en) A-33 related antigens and their pharmacological uses
EE200100123A (et) CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon
IL152961A0 (en) Inhibitors of alpha beta 2 mediated cell adhesion
JPS615392B2 (es)
AU2672099A (en) Compositions and methods for wound healing
AU6865600A (en) Cell proliferation inhibitory protein, polynucleotide, antisense polynucleotide to the polynucleotide, and cell proliferation inhibitors, cancer diagnostics, cancer remedies and compositions for gene therapy by using the same
RU2007119777A (ru) Антисмысловые олигонуклеотиды для лечения аллергии и пролиферации неопластических клеток
WO2003106681A3 (de) Antisense oligonukleotide gegen pim1
GB9320548D0 (en) Improvements in or relating to organic compounds
IL160408A0 (en) Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides
EP1546180A4 (en) USE OF ANTISENSE OLIGONUCLEOTIDES TO INHIBIT THE EXPRESSION OF AKT-1
AU3934000A (en) Inhibitors of endothelin-1 synthesis

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: TOPIGEN PHARMACEUTIQUES INC.

FG Grant or registration
MM Annulment or lapse due to non-payment of fees